1. Home
  2. BLLN vs LAZ Comparison

BLLN vs LAZ Comparison

Compare BLLN & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BillionToOne Inc.

BLLN

BillionToOne Inc.

HOLD

Current Price

$104.82

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Logo Lazard Inc.

LAZ

Lazard Inc.

HOLD

Current Price

$36.77

Market Cap

4.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLLN
LAZ
Founded
2016
1848
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.4B
IPO Year
2025
2004

Fundamental Metrics

Financial Performance
Metric
BLLN
LAZ
Price
$104.82
$36.77
Analyst Decision
Buy
Hold
Analyst Count
7
8
Target Price
$126.71
$52.75
AVG Volume (30 Days)
501.7K
1.2M
Earning Date
05-06-2026
05-01-2026
Dividend Yield
N/A
4.21%
EPS Growth
103.40
N/A
EPS
0.48
0.91
Revenue
$305,112,000.00
$3,186,466,000.00
Revenue This Year
$46.29
$13.36
Revenue Next Year
$30.14
$13.72
P/E Ratio
$220.69
$39.26
Revenue Growth
99.97
1.48
52 Week Low
$61.96
$35.16
52 Week High
$150.44
$58.75

Technical Indicators

Market Signals
Indicator
BLLN
LAZ
Relative Strength Index (RSI) 53.45 31.71
Support Level $79.07 N/A
Resistance Level $108.50 $45.71
Average True Range (ATR) 5.08 2.06
MACD 1.86 -0.78
Stochastic Oscillator 64.44 12.64

Price Performance

Historical Comparison
BLLN
LAZ

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

About LAZ Lazard Inc.

Lazard Inc is a financial advisory and asset management firm with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Geographically, the company earns key revenue in the Americas, EMEA then Asia-Pacific.

Share on Social Networks: